Myeloma Merchandise & Free Publications

Abecma® (idecabtagene vicleucel, "ide-cel") is the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for use in myeloma. Abecma is a personalized immune cell therapy delivered as a one-time infusion, manufactured for each individual patient using the patient's own white blood cells (T cells).

This Tip Card provides practical advice on how to protect your medical records.

Bispecific antibody therapies are a combination of two immunotherapy approaches in one drug. Bispecifics are comprised of two monoclonal antibodies that bind to two different antigens and trigger the immune system to destroy the patient's myeloma cells.

Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen (BCMA), coupled with monomethyl auristatin F (MMAF), a drug that can kill myeloma cells.

Darzalex® (daratumumab) is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. The original formulation of Darzalex is administered as an intravenous infusion, and the FDA has also approved Darzalex Faspro® (daratumumab + hyaluronidase-fihj) as a subcutaneous injection. Both formulations are available as monotherapy and as part of combination therapies.

Early diagnosis is key to achieving best outcomes for patients.

This Tip Card discusses Empliciti (elotuzumab) for the treatment of multiple myeloma.

Order this Tip Card about blood tests that measure light chains (Freelite) and immunoglobulin pairs (Hevylite).

This Tip Card discusses Kyprolis (carfilzomib) for the treatment of multiple myeloma.

Order this Tip Card to gain information on how to manage immunosuppression.

This Tip Card discusses the Myeloma Matrix 2.0: Smart Search, a clinical trial search tool.

This tool was developed in collaboration with myeloma patients and caregivers, leaders of myeloma support groups, and the IMF Nurse Leadership Board. Discuss this tool with your treatment team and healthcare providers.

This Tip Card discusses Ninlaro (ixazomib) for the treatment of multiple myeloma.

This Tip Card discusses Pomalyst (pomalidomide) for the treatment of multiple myeloma.

Sarclisa is a novel monoclonal antibody directed against the CD38 receptor on the surface of myeloma cells.

The triplet VRd regimen is approved in the United States and in the European Union for patients with previously untreated myeloma who are ineligible for transplant. The VRd combination is highly effective and well tolerated.

This information is in an easy-to-carry format and covers key treatments and care issues.

Xpovio is a nuclear export inhibitor to treat Myeloma.

This Tip Card provides practical advice on how to protect your medical records.

Understanding ABECMA® (idecabtagene vicleucel) focuses on the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for use in myeloma.

Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen (BCMA), coupled with monomethyl auristatin F (MMAF), a drug that can kill myeloma cells.

Clinical trials are research studies of new treatments that involve patients. Whether or not to participate in a clinical trial is one of the critical decisions you and your oncologist may have to make at some point in the cancer care continuum.

Darzalex® (daratumumab) is a laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells.

After reading this booklet, you should know what Dexamethasone is, how it works, possible side effects, and more.

Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication, Understanding the Immune System in myeloma.

Myeloma patients may experience fatigue caused by the disease, by treatment, and by the understandable anxiety and/or depression that affects many. This booklet contains a thorough examination of coping strategies and causes of myeloma fatigue, as well as suggestions for discussing fatigue with your doctor.

High-dose therapy with stem cell rescue, or "stem cell transplant", is an important treatment option for eligible patients with multiple myeloma.

This booklet discusses Kyprolis® (carfilzomib), the results of clinical trials with Kyprolis®, how and when it is administered, its possible side effects, and how to manage them.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are not active disease states, but both are precursor states to active myeloma. It is therefore important to understand if, when, and how active myeloma might evolve and what monitoring and/or interventions are appropriate.

Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.

Peripheral neuropathy (PN) is a complication of myeloma involving damage to the nerves of the peripheral nervous system that can be caused both by myeloma and by treatments for myeloma.

Pomalyst® (pomalidomide) in combination with Dexamethasone was approved by the U.S. Food and Drug Administration (FDA) on February 8, 2013 for relapsed and refractory myeloma.

Revlimid® (lenalidomide) has been approved by the FDA for use in myeloma.

Sarclisa is a novel anti-CD38 monoclonal antibody. Although antibodies are a naturally-occurring part of the immune system, Sarclisa and other antibodies used to treat diseases are made in a laboratory. A laboratorymade antibody is designed to function like a naturally-occurring antibody, and to bind to a specific single protein on the surface of the targeted cells (in this case, myeloma cells). In this sense, Sarclisa is a targeted antimyeloma therapy.

Using Thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. Much has been learned about how Thalidomide works in the treatment of different diseases, and how its side effects can be treated.

This booklet will help you understand immune system basics. The immune system is extremely complex. It is made up of multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer.

This booklet will familiarize you with the way this combination therapy works, how it has been tested in clinical trials, the indication for which it is approved, how and when it is administered, its possible side effects and their management, and special precautions you need to take while taking VRd.

This booklet is focused on therapies given to patients with myeloma bone involvement. Bisphosphonate therapy is not treatment for myeloma, but it does help to prevent skeletal complications of myeloma. Monoclonal antibody therapy targets a protein which controls bone regeneration and remodeling.

As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress placed upon it.

This booklet covers the basics of FDA approved VELCADE® (bortezomib), including how it works, how it is administered, how is it used in clinical practice today, and side effects.

Xpovio, a new medication to treat myeloma, is a "nuclear export inhibitor," the first compound in this new drug class. Nuclear export inhibitors prevent cancer cells from expelling special genes in the cell nucleus called tumor suppressor proteins that help protect the cell from cancer.

This booklet outlines the tests that are used to diagnose and monitor myeloma, and to detect response and relapse. No single study is adequate to tell the whole story about a patient's status but, used together, test results give a more complete picture.